S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

Immunome Stock Forecast, Price & News

-0.76 (-2.48 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $29.84
50-Day Range
MA: $23.82
52-Week Range
Now: $29.84
Volume99,218 shs
Average Volume386,460 shs
Market Capitalization$314.57 million
P/E RatioN/A
Dividend YieldN/A
Immunome Inc., a biotechnology company, discovers, develops, and commercializes highly targeted and native human cancer antibodies against universal cancer antigens. Its RealMAb technology enables the discovery of novel antigens and the cognate native human antibodies that target antigens; and ScreenMab multiplex functional screening technology identifies monoclonal antibodies that have exquisite for tumor neoantigens. The company was founded in 2006 and is based in Exton, Pennsylvania.
Immunome logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:IMNM
Phone610 321 3700
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$314.57 million
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.09 out of 5 stars

Medical Sector

967th out of 1,972 stocks

Pharmaceutical Preparations Industry

456th out of 772 stocks

Analyst Opinion: 1.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
-0.76 (-2.48 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IMNM News and Ratings via Email

Sign-up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Immunome (NASDAQ:IMNM) Frequently Asked Questions

Is Immunome a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunome in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Immunome stock.
View analyst ratings for Immunome
or view top-rated stocks.

What stocks does MarketBeat like better than Immunome?

Wall Street analysts have given Immunome a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Immunome wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Immunome?

Immunome saw a increase in short interest during the month of February. As of February 12th, there was short interest totaling 71,800 shares, an increase of 86.0% from the January 28th total of 38,600 shares. Based on an average daily volume of 262,700 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.9% of the company's shares are sold short.
View Immunome's Short Interest

When is Immunome's next earnings date?

Immunome is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Immunome

What price target have analysts set for IMNM?

2 equities research analysts have issued 1 year target prices for Immunome's shares. Their forecasts range from $18.00 to $18.00. On average, they anticipate Immunome's stock price to reach $18.00 in the next twelve months. This suggests that the stock has a possible downside of 39.7%.
View analysts' price targets for Immunome
or view top-rated stocks among Wall Street analysts.

Who are Immunome's key executives?

Immunome's management team includes the following people:
  • Dr. Purnanand Duddu Sarma, Pres, CEO & Director (Age 56, Pay $503.24k)
  • Dr. Michael J. Morin, Chief Scientific Officer (Age 66, Pay $363.77k)
  • Ms. Diane M. Marcou CPA, Interim Chief Financial Officer (Age 55)
  • Sandra G. Stoneman Esq., Chief Legal Officer & Corp. Sec.
  • Mr. Matthew K. Robinson Ph.D., Sr. VP of R&D

Who are some of Immunome's key competitors?

When did Immunome IPO?

(IMNM) raised $30 million in an initial public offering (IPO) on Friday, October 2nd 2020. The company issued 2,500,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Chardan served as the underwriters for the IPO.

What is Immunome's stock symbol?

Immunome trades on the NASDAQ under the ticker symbol "IMNM."

When does the company's lock-up period expire?

Immunome's lock-up period expires on Wednesday, March 31st. Immunome had issued 3,250,000 shares in its public offering on October 2nd. The total size of the offering was $39,000,000 based on an initial share price of $12.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.

Who are Immunome's major shareholders?

Immunome's stock is owned by many different retail and institutional investors. Top institutional shareholders include Prentice Capital Management LP (3.95%), Cerity Partners LLC (1.16%), BlackRock Inc. (0.68%), Granite Point Capital Management L.P. (0.63%), Kepos Capital LP (0.63%) and Northern Trust Corp (0.24%).
View institutional ownership trends for Immunome

Which institutional investors are buying Immunome stock?

IMNM stock was purchased by a variety of institutional investors in the last quarter, including Prentice Capital Management LP, Cerity Partners LLC, BlackRock Inc., Kepos Capital LP, Granite Point Capital Management L.P., Northern Trust Corp, JPMorgan Chase & Co., and New York State Common Retirement Fund.
View insider buying and selling activity for Immunome
or or view top insider-buying stocks.

How do I buy shares of Immunome?

Shares of IMNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immunome's stock price today?

One share of IMNM stock can currently be purchased for approximately $29.84.

How much money does Immunome make?

Immunome has a market capitalization of $314.57 million.

How many employees does Immunome have?

Immunome employs 21 workers across the globe.

What is Immunome's official website?

The official website for Immunome is immunome.com.

How can I contact Immunome?

The company can be reached via phone at 610 321 3700 or via email at [email protected]

This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.